Antengene Corporation Limited a leading innovative biopharmaceutical company dedicated to discovering developing and commercializing global firstinclass andor bestinclass therapeutics in hematology and oncology
ABEC a global provider of integrated solutions and services for biopharmaceutical manufacturing announced it will design manufacture and install multiple L fermenter trains for HEC Pharms manufacturing site in Guangzhou China
Celcuity Inc a clinicalstage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer today announced it has entered into a global licensing agreement with Pfizer Incgranting Celcuity exclusive rights to Pfizers gedatolisib a Phase...
Context Therapeutics a clinicalstage womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormonedriven breast and gynecological cancers
RedHill Biopharma Ltd a specialty biopharmaceutical company announced that the global Phase study with orallyadministered opaganib Yeliva ABC in patients hospitalized with severe COVID pneumonia has received a unanimous recommendation
GenScript Biotech Corporation Parkway Laboratories and the Diagnostics Development DxD Hub announced their collaboration to provide the cPass SARSCoV neutralizing antibody test in Singapore through Parkways panel of specialist and GP clinics
Cosmo Pharmaceuticals NV today announced the FDA approval of GI Genius intelligent endoscopy system its revolutionary device for lesion detection during colonoscopyThe GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than years of research and investments focused to gene...
Aprea Therapeutics Inc a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p today announced that the US Food and Drug Administration FDA has granted Orphan Drug designation to eprenetapopt for treatment...
Holiday Inn London - Heathrow M4
PARTNERSHIPCodexis Inc and Porton Pharma Solutions Ltd announce a strategic collaboration to deploy Codexis worldleading biocatalyst technology within Portons global custom intermediate and active pharmaceutical ingredients API development and manufacturing business The partnership will accelerate the creation and commercialization of new lowcost sustainable manufacturing processes exploiting the benefits of...
Monotonic dose dependence is often regarded as evidence that the drug is effective It is supposed to be used as a criterion to seek genes whose expression is specifically affected On the other hand multiple dose treatment can cause more complicated dose dependence eg convex Excluding genes that exhibit nonmonotonic
Kristian Pietras Jessica Pahler Gabriele Bergers Douglas Hanahan Department of Biochemistry and Biophysics Diabetes Center and Comprehensive Cancer Center University of California San Francisco San Francisco California United States of America Ludwig Institute for Cancer Research Karolinska Institutet Sto
Abstract Purpose To compare the effects of nine months of exercise training and ibuprofen supplementation given immediately after exercise sessions on bone and muscle in postmenopausal women Methods In a doubleblin
Novartis Promacta is approved as the firstline treatment for adults and pediatric patients two years and older with Severe Aplastic Anemia SAA in combination with standard immunosuppressive therapy IST Promacta is an oral thrombopoietin receptor agonist TPORA that is already approved for SAA for patients who have had an insufficient response to IST It can also b...
Vaishnavi Loganathan Research Analyst Beroe Inc Abstract The drugs which are developed for the treatment of rare diseases diseases which affect a very small population are called Orphan Drugs The Governments of various countries provide incentives and patent exclusivities in order to encourage orpha
Modelling and simulation has been growing rapidly in impact and is now actively used by biopharmaceutical companies worldwide for drug development and...